Jin Medical Regains Nasdaq Compliance After Reverse Stock Split

summarizeSummary

Jin Medical International Ltd. announced it has regained compliance with Nasdaq's minimum bid price requirement, resolving a delisting threat after its shares maintained a bid price above $1.00 following a recent reverse stock split.

check_boxKey Events

• Nasdaq Compliance Regained

  The company received written notice from Nasdaq confirming it has regained compliance with Listing Rule 5550(a)(2), the Minimum Bid Price Requirement.

• Sustained Bid Price

  Compliance was achieved as the closing bid price of the company's Class A ordinary shares remained at $1.00 or greater for 13 consecutive business days, from March 16, 2026, to April 1, 2026.

• Follows Reverse Stock Split

  This compliance follows the 1-for-20 reverse stock split, which became effective with Nasdaq on March 16, 2026, an action previously disclosed on March 17, 2026, to address the bid price deficiency.

• Resolution of Delisting Threat

  This resolves the deficiency letter received on May 2, 2025, and the subsequent compliance periods granted by Nasdaq.

auto_awesomeAnalysis

This filing confirms Jin Medical International Ltd. has successfully regained compliance with Nasdaq's minimum bid price requirement. This is a significant positive development as it removes the immediate threat of delisting, which had been an ongoing concern since May 2025. The compliance was achieved after the company's Class A ordinary shares maintained a closing bid price of $1.00 or greater for 13 consecutive business days, following a 1-for-20 reverse stock split that became effective on March 16, 2026. For a micro-cap company, avoiding delisting is crucial for maintaining investor access and liquidity.